RP
AERI

Raiff Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Raiff Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,000
Closed -$251K – 52
2015
Q1 		$251K Buy
+8,000
New +$232K 0.24% 36

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raiff Partners's AERI Position: Q2 2015 in Review

Raiff Partners sold out of Aerie Pharmaceuticals (AERI) in Q2 2015, closing a stake of 8,000 shares — an estimated $251K sold.

Raiff Partners first reported a position in AERI in Q1 2015 and held it in 1 quarter. The position peaked at $251K in Q1 2015. 108 funds tracked by Wall St. Rank hold AERI as of Q2 2015.

  • Raiff Partners reported no remaining Aerie Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Raiff Partners sold 8,000 Aerie Pharmaceuticals shares in Q2 2015, an estimated $251K.
  • Raiff Partners first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Raiff Partners's Aerie Pharmaceuticals position peaked at $251K in Q1 2015.
  • 108 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2015.

Based on Raiff Partners's 13F filing for Q2 2015, filed 13 Aug 2015.